Editorial Board

Prof. Gabriel Lopez-Berestein, M.D.

Prof. Gabriel Lopez-Berestein, M.D.
Professor of Medicine, Cancer Biology, and Experimental Therapeutics
Department of Experimental Therapeutics, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
USA

Biography :

Dr. Gabriel Lopez-Berestein is a Professor in the Department of Experimental Therapeutics at MD Anderson Cancer Center (MDACC) and served as the Executive Director of the MDACC Pharmaceutical Development Center. He is internationally known for his research pertaining to development of nanomedical applications that has resulted in more than 200 patents and clinical trials and the FDA-approved drug, Abelcet™ (liposomal amphotericin-B), which is available worldwide and considered standard treatment for life-threatening fungal infections. For the last 30 years Dr. Lopez-Berestein has been studying different aspects of cell death and differentiation and cell signaling.

Research Interest :

Immunology, Internal Medicine, Oncology-Developmental Therapeutics